TY - JOUR
T1 - Patient assessment of bowel function during and after pelvic radiotherapy
T2 - Results of a prospective phase III north central cancer treatment group clinical trial
AU - Haddock, Michael G.
AU - Sloan, Jeff A.
AU - Bollinger, John W.
AU - Soori, Gamini
AU - Steen, Preston D.
AU - Martenson, James A.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2007/4/1
Y1 - 2007/4/1
N2 - Purpose: To evaluate patient assessment of long-term effect of pelvic radiotherapy on bowel function. Patients and Methods: As part of a prospective randomized trial evaluating the impact of sucralfate on bowel function in patients receiving pelvic radiotherapy, patient-assessed bowel function data were collected during radiotherapy and again at 4 weeks and 1 year after completion of radiotherapy. Results: The number of bowel movements per day increased up to week 4 and then slowly decreased. At 1 year, the mean number of bowel movements per day had increased from 1.75 to 2.09 and the median from 1 to 2. All measures of adverse bowel function worsened during radiotherapy. Frequency of bowel movements and symptoms of frequency, nocturnal bowel movements, cramping, and bleeding returned close to baseline values by 1 year. Symptoms of urgency, clustering, and measures of incontinence were all persistent at 1 year. The mean increase in bowel function score at 1 year was 0.74 (range, -5 to 7). Conclusion: Pelvic radiotherapy is associated with a slight increase in bowel movement frequency and decrease in several patient-reported measures of adverse bowel function. Several measures of adverse function persisted at 1 year.
AB - Purpose: To evaluate patient assessment of long-term effect of pelvic radiotherapy on bowel function. Patients and Methods: As part of a prospective randomized trial evaluating the impact of sucralfate on bowel function in patients receiving pelvic radiotherapy, patient-assessed bowel function data were collected during radiotherapy and again at 4 weeks and 1 year after completion of radiotherapy. Results: The number of bowel movements per day increased up to week 4 and then slowly decreased. At 1 year, the mean number of bowel movements per day had increased from 1.75 to 2.09 and the median from 1 to 2. All measures of adverse bowel function worsened during radiotherapy. Frequency of bowel movements and symptoms of frequency, nocturnal bowel movements, cramping, and bleeding returned close to baseline values by 1 year. Symptoms of urgency, clustering, and measures of incontinence were all persistent at 1 year. The mean increase in bowel function score at 1 year was 0.74 (range, -5 to 7). Conclusion: Pelvic radiotherapy is associated with a slight increase in bowel movement frequency and decrease in several patient-reported measures of adverse bowel function. Several measures of adverse function persisted at 1 year.
UR - http://www.scopus.com/inward/record.url?scp=34247160450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247160450&partnerID=8YFLogxK
U2 - 10.1200/JCO.2006.09.0001
DO - 10.1200/JCO.2006.09.0001
M3 - Article
C2 - 17401014
AN - SCOPUS:34247160450
SN - 0732-183X
VL - 25
SP - 1255
EP - 1259
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 10
ER -